ARCT SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

NT 10-Q

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Nov 10, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress

Nov 5, 2026

8-K

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results, Next-Generation LUNAR 2.0™ Platform, and Acquisition of myNEO

Sep 23, 2026

8-K

Arcturus Therapeutics to Present ARCT-810 Clinical Data at 2026 SSIEM Annual Symposium

Aug 25, 2026

8-K

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Aug 6, 2026

8-K

Arcturus Therapeutics Enters Strategic Manufacturing and Clinical Collaboration with Thermo Fisher Scientific for ARCT-032

Jul 2, 2026

8-K

Arcturus Therapeutics Holdings Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Common Stock

Aug 7, 2023

424B5

1,365,000 Shares-

Dec 8, 2020

424B5

Common Stock-

Dec 7, 2020

424B5

3,264,151 Shares

Jul 30, 2020

424B5

Common Stock

Jul 28, 2020

424B5

4,117,650 Shares

Apr 17, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-3

December 2025 SHELF and ATM

Dec 30, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 17, 2024

S-3

Common Stock

Dec 23, 2022

S-8

Registration

Jun 30, 2022

S-8

1,000,000

Oct 20, 2021

S-3ASR

Common Stock-

Dec 7, 2020

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A